{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["41(10)"],"submitter":["Isnardi CA"],"pubmed_abstract":["<h4>Background/objective</h4>To evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with rheumatic and immune-mediated inflammatory diseases (IMIDs) in Argentina: the SAR-CoVAC registry.<h4>Methods</h4>SAR-CoVAC is a national, multicenter, and observational registry. Adult patients with rheumatic or IMIDs vaccinated for SARS-CoV-2 were consecutively included between June 1 and September 17, 2021. Sociodemographic data, comorbidities, underlying rheumatic or IMIDs, treatments received, their modification prior to vaccination, and history of SARS-CoV-2 infection were recorded. In addition, date and place of vaccination, type of vaccine applied, scheme, adverse events (AE), disease flares, and new immune-mediated manifestations related to the vaccine were analyzed.<h4>Results</"],"journal":["Clinical rheumatology"],"pagination":["3199-3209"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9244362"],"repository":["biostudies-literature"],"pubmed_title":["An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data."],"pmcid":["PMC9244362"],"pubmed_authors":["Isnardi CA","Tissera Y","Kogan N","Cosatti MA","Pisoni CN","Bertoli A","Luna PC","Pons-Estel GJ","Zelaya MD","de Los Angeles Severina M","Alonso C","Exeni MED","Retamozo C","Elkin MSG","Cosentino V","Cogo AK","De Los Angeles Correa M","Pereira D","Petkovic I","Schneeberger EE","Rosemffet M","Mussano E","Echeverria C","de la Vega MC","Quintana R","Garcia L","Kreimer JL","Landi M","Nieto RE","Savio VG","Roberts K","Virasoro BM"],"additional_accession":[]},"is_claimable":false,"name":"An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.","description":"<h4>Background/objective</h4>To evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with rheumatic and immune-mediated inflammatory diseases (IMIDs) in Argentina: the SAR-CoVAC registry.<h4>Methods</h4>SAR-CoVAC is a national, multicenter, and observational registry. Adult patients with rheumatic or IMIDs vaccinated for SARS-CoV-2 were consecutively included between June 1 and September 17, 2021. Sociodemographic data, comorbidities, underlying rheumatic or IMIDs, treatments received, their modification prior to vaccination, and history of SARS-CoV-2 infection were recorded. In addition, date and place of vaccination, type of vaccine applied, scheme, adverse events (AE), disease flares, and new immune-mediated manifestations related to the vaccine were analyzed.<h4>Results</","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-27T19:32:17.958Z","creation":"2022-07-08T18:24:30.928Z"},"accession":"S-EPMC9244362","cross_references":{"pubmed":["35760939"],"doi":["10.1007/s10067-022-06253-5"]}}